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Antithrombin and protein C are important anti-
coagulant proteins.1 After the activation of protein
C on the endothelial surface by the complex forma-
tion of thrombin, thrombomodulin, and protein C,
protein C inhibits the coagulation cascade via prote-
olytic degradation of coagulation factors Va and
VIIIa. These phospholipid cell membrane reactions
are potentiated by protein S.2 Recently, we demon-
strated such potentiation with APC resistance or
abnormalities in factor V.3 APC resistance is caused
by a defect in factor V caused by a single point muta-
tion of Arg506 to Gln (factor V Leiden).4–6 This
mutation is found in 40% to 50% of patients with
venous thromboembolism.7–11 For screening of
APC resistance, an APC-ratio test has been used.
Abnormal APC ratio is in a venous cohort due to
factor V Leiden gene mutation in 75% to 95% of
patients.12–14 Thus, the factor V Leiden gene muta-
tion causing APC resistance was found with a 10-
fold increased prevalence in such patients, compared
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Purpose: The frequency of activated protein C (APC) resistance, caused by factor V
R506Q gene mutation and abnormal APC ratio, in patients with peripheral vascular dis-
eases was analyzed.
Methods: All patients electively admitted to the vascular ward unit of our tertiary care
academic medical center from January 1995 through October 1996 (n = 679) were
prospectively analyzed using an APC-resistance screening test to determine the frequen-
cy of abnormal APC ratio (≤2.6). Baseline activated partial thromboplastin time (APTT)
and its prolongation after the addition of a standard amount of APC were determined.
The factor V R506Q gene mutation (Leiden) was analyzed in patients with an APC ratio
less than 3.0. Statistical comparisons were made to an age-matched control population
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Results: The factor V Leiden gene mutation or abnormal APC ratio was detected in 154
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P < .001). The factor V Leiden gene mutation was found in 102 patients (15.2%), com-
pared with 29 control subjects (10.4%; t = 4.64; P < .05); an abnormal APC ratio was
found in 132 patients (19.8%), compared with 26 (9.8%) of controls (t = 14.56; 
P < .001). The frequency of the factor V Leiden gene mutation was significantly
increased in patients with femoro-popliteal occlusive disease (n = 126), to 21.6% (t =
16.94; P < .001), and venous disease (n = 50), to 36.0% (t = 20.93; P < .001). Overall,
63% of the patients with abnormal APC ratios tested positive for the factor V Leiden
gene mutation. A significantly increased frequency of APC resistance was demonstrated
in patients undergoing aorto-iliac (n = 37) or femoro-crural graft reconstructions (n =
72); it was found in 41% and 35%, respectively (P < .001). In addition, a significantly
increased frequency of APC resistance was found in patients who suffered from occlu-
sion after reconstruction; 13 of 41 (32%) had the factor V Leiden gene mutation (P <
.001), and 19 of 39 (49%) had an abnormal APC ratio (P < .001).
Conclusion: The factor V Leiden gene mutation and abnormal APC ratios are signifi-
cantly increased in patients with lower extremity peripheral vascular disease and failed
reconstructions. An abnormal APC ratio was seen without factor V Leiden gene muta-
tion in 37% of patients with peripheral vascular diseases, suggesting additional causes of
an abnormal APC ratio, exclusive of gene mutation. (J Vasc Surg 1998;28:624-9.)
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with other inherited anticoagulant protein deficien-
cies; however, this does not account for all cases of
an abnormal APC ratio.10 The true prevalence of
APC resistance in the general population remains to
be determined. In healthy control subjects, a 3% to
11% incidence is reported.8–11 Important geograph-
ical and racial differences have been found. In the
Malmö, Sweden, general population, a frequency
from 7% to 11% of APC resistance has been con-
firmed.10,15,16
APC resistance or the defect in factor V Leiden is
characterized by an abnormal anticoagulant response
to activated protein C.2 APC resistance can be
screened for with an assay that determines the antico-
agulant response to APC in an activated partial throm-
boplastin time (APTT) reaction. Although this assay
has been standardized, high levels of fibrinogen, factor
VIII, and antiphospholipid syndromes may cause
abnormal results.13,17 In addition, the assay cannot be
performed on patients receiving oral anticoagulants or
heparin. Although modifications of the test may be
more specific, demonstration of the factor V Leiden
gene mutation remains the most specific test.6,12,13
On the basis of our observation that APC resis-
tance was frequent in patients with early femoro-
crural graft occlusion,18,19 the frequency of APC
resistance and abnormal APC ratios without the fac-
tor V Leiden gene mutation was studied in patients
with peripheral vascular disease.
PATIENTS AND METHODS
Between January 1995 and October 1996, 679
patients underwent APC-resistance analysis. All
patients had blood sampling 2 to 3 days before elec-
tive admittance to the vascular surgery ward unit. This
prospective and consecutive analysis of elective
patients included determination of activated partial
thromboplastin time (APTT; automated, Organon
Teknika) and simultaneous analysis of the anticoagu-
lant effect after the addition of a standardized amount
of APC, 20 nmol/L human APC in 10 mmol/L Tris
HCl/0.05 mol/L NaCl/30 mmol/L CaCl2, 0.1%
bovine serum albumin at pH 7.5 (Chromogenix AB,
Mölndal, Sweden)2. The APC ratio was the ratio of
clotting time with and without the addition of APC.
An abnormal APC ratio was set at 2.6 or less.10 In
patients with an APC ratio of 3.0 or less, determina-
tion of the factor V Leiden gene was made with PCR-
amplifying technique with 2 primers for confirmation
of the mutation, as previously described.12
Fig 1. The individual APC ratios and their distribution in the different groups. The line indi-
cates the median valve.
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Calculation of the sample size was on the basis of
the frequency of APC resistance in age-matched and
sex-matched control subjects from the city of
Malmö, where 29 of 278 of the control subjects dis-
played the factor V Leiden gene mutation and 26
had abnormal APC ratios (≤2.6). The median age of
control subjects was 57 years.16 For a difference in
frequency of 5%, the material size needed to be
approximately equal to 500 patients; for a 10% dif-
ference, the material size needed to be approximate-
ly equal to 100 patients.
Based on the most significant arteriosclerotic
lesion, patients were divided into groups: those with
carotid disease (stenosis normally >70%), those with
abdominal aortic aneurysm (diameter >5 cm), those
with aorto-iliac occlusive disease (<200 m walking
distance), those with femoro-popliteal occlusive dis-
ease (critical ischemia), or those with venous disease.
The group classified as other peripheral vascular dis-
eases included patients with fibromuscular dysplasia,
thromboangiitis obliterans, and upper extremity
ischemia.
The statistical significance of variables between
patients with peripheral vascular disease and the
Malmö control group was determined with c 2
analysis. Significance was assumed when a P value of
less than .05 was achieved.
RESULTS
Of the 679 consecutive patients, factor V Leiden
gene mutation or an APC ratio of 2.6 or less was
found in 154 patients (22.7%), compared with 34 of
the 278 (12.2%) Malmö control subjects (t = 13.65;
P < .001). The factor V Leiden gene mutation was
seen in 102 patients (15.2%; t=4.64; P < .05), and an
abnormal APC ratio was found in 132 patients
(19.8%; t = 14.56; P < .001). Subgroup analysis is
illustrated in Tables I and II and Fig 1. An increased
frequency (P < .01 for APC and P < .001 for abnor-
mal APC ratio) was noted in patients with arte-
riosclerotic lesion in the femoro-popliteal segment
and in patients with venous diseases (P < .001), as
compared with the control group.
As shown in Table I, APC-ratio testing was not
possible in 11 patients because of current oral anti-
coagulation therapy; however, factor V Leiden gene
mutation was possible. Factor V Leiden gene muta-
tion was demonstrated in 11 patients with an APC
ratio of 2.6 or less. In 6 patients with abnormal APC
ratios and in 10 patients with ratios between 2.7 and
3.0, the factor V Leiden gene mutation test was not
performed (Fig 2).
The age distribution of the 679 patients is illus-
trated in Fig 3. The median age was 70 years, which
is similar to the median age of 72 years for the
groups of patients with carotid, aorto-iliac, and
femoro-popliteal occlusive disease. Patients with
abdominal aortic aneurysmal disease and venous dis-
ease were slightly younger, with median ages of 65
years and 53 years, respectively.
The frequency of factor V Leiden gene mutation
and abnormal APC ratio based on patient age are
shown in Table III. There was a trend for APC resis-
tance to decrease with age (t = 1.99, NS). However,
the frequency of abnormal APC ratios did remain
unchanged. Therefore, the number of patients with
abnormal APC ratios and normal factor V Leiden
gene mutation tests increased with age, from a fre-
quency of 0.7% for those 61 years or younger to
5.5% in patients older than 61 years.
Patients undergoing aorto-iliac graft reconstruc-
tions (n = 37) and femoro-crural reconstructions (n
Table I. Number of patients with APC resistance and abnormal APC-test for different categories 
of arteriosclerosis
Positive Positive Positive Normal Factor
factor factor factor factor V gene 
V gene V gene V gene V gene mutation
mutation, mutation mutation mutation, not done,
Number but APC test and normal and abnormal but abnormal but normal
of patients not possible APC test APC test APC test APC test
Control group 278 8 21 5
Carotid disease 116 1 10 1 1
Abdominal aortic aneurysm 93 3 2 7 5
Aorto-iliac occlusive disease 233 5 2 23 15 4
Femoro-popliteal occlusive disease 126 2 3 22 18 1
Venous disease 50 2 16 3
Other 61 1 1 2 4
Total vascular patients 679 11 11 80 46 6
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= 72) had a high frequency of factor V Leiden gene
mutation and abnormal APC ratios (41% and 43%,
35% and 46%, respectively), compared with the con-
trol population (t = 22.64-38.76, P<.001). Overall,
of those that underwent operations, graft occlusion
occurred in 41 patients. Of these patients with
occluded grafts, 13 of 41 (32%; t = 12.94; P < .001)
had factor V Leiden gene mutation, and 19 of 39
(49%) had abnormal APC ratios (t = 36.90; 
P < .001). 
DISCUSSION
The impact of APC resistance on the develop-
ment of peripheral arterial thrombosis remains to be
defined. This study was undertaken to determine the
frequency of the factor V Leiden gene mutation
(APC resistance) and the frequency of abnormal
APC ratio in patients with peripheral vascular disease. 
The incidence of APC resistance, validated with
factor V Leiden gene analysis in patients with myocar-
dial infarction, has been reported to be a frequency
between 2.5% to 18%, compared with a frequency in
control subjects of 0.7% to 11%.15,20,21.Given this
wide variability, further studies, with subgroup-analy-
sis, will be required to determine whether an increase
in the frequency of APC resistance exists in these
patients.
In patients who had strokes, one study, which
did not validate results with factor V Leiden gene
analysis, showed a 20% incidence of APC resis-
tance11; however, other studies validated with factor
V Leiden gene mutation analysis have found a fre-
quency approximately equal to 5% both in patients
who have had strokes and in control popula-
tions.22–24 This is in accordance with our results. 
APC resistance in patients with peripheral vascu-
lar disease is only reported in 2 studies.25–26 One of
these studies, not validated with factor V Leiden
gene mutation analysis, included 173 patients with
peripheral vascular disease and reported a 5% inci-
dence rate of abnormal APC ratio in patients who
have had strokes, 11.5% in patients with aneurysmal
disease, and 13.7% in patients with lower extremity
arteriosclerosis. With a normalized sensitivity ratio
(NSR), abnormal APC ratio was documented in
10.6% to 22.0% of patients with peripheral vascular
disease.26 Interestingly, Ouriel et al found that 5 of
10 infrainguinal reconstructions in patients with
abnormal APC ratios occluded within the first year.
In a retrospective analysis of 23 occluded infrain-
guinal reconstructions at our institution, 64% of
occlusions within 1 month occurred in patients with
abnormal APC ratios.19 Therefore, the identification
and treatment of patients with abnormal APC ratios
before arterial reconstruction could optimize these
results. Further studies are needed.
In the present study, a high incidence of the fac-
tor V Leiden gene mutation and abnormal APC
ratios was found in patients with aorto-iliac and
femoro-popliteal occlusive disease and venous dis-
ease. This confirms results from earlier studies.25,26
In this study, the frequency of factor V Leiden gene
mutation or abnormal APC ratio in patients with
carotid disease and abdominal aortic aneurysmal dis-
ease was not significantly different than in control
subjects. These findings regarding patients with
carotid disease strongly support earlier studies.22–24
Fig 2. The distribution of APC ratios and their relation
to factor V gene mutation.
Fig 3. Age distribution for 679 elective patients with
peripheral arteriosclerosis and venous disease at a vascular
surgical ward unit. The findings of factor V gene mutation
is also shown.
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For patients with abdominal aortic aneurysmal dis-
eases, the frequency of factor V Leiden gene muta-
tion and/or abnormal APC ratio was equal to con-
trol populations, contrary to the findings of Ouriel
et al, who noted an increased frequency.25
Younger patients displayed a higher frequency of
the factor V Leiden gene mutation. The frequency
of a mutation must be the same in different age
groups. However, one reason for our reported dif-
ference could be that arteriosclerotic patients with
the factor V Leiden gene mutation may have earlier
occlusions and, therefore, earlier symptoms of their
peripheral vascular disease. In the same way, patients
with lower extremity arteriosclerosis and the factor
V Leiden gene mutation may occlude longer seg-
ments, giving more severe symptoms that more fre-
quently require vascular reconstruction.
In the present study, the factor V Leiden gene
mutation assay was performed on 98% of the
patients at risk of having APC resistance (ie, APC
ratio <3.0). Surprisingly, only 67% of patients with
abnormal APC ratios had verification of factor V
Leiden gene mutation. In contrast, studies of venous
thrombosis patients have demonstrated a factor V
Leiden gene mutation in 75% to 95% of patients
with abnormal APC ratios.10,15 This discrepancy
may be caused by differences in patient population.
Peripheral vascular surgery patients are known to
have a higher frequency of coagulation; high fi-
brinogen, high factor II, V, VIII, IX, X, or anticoag-
ulation; antiphospholipid syndrome—defects known
to interfere with the APC-resistance screening
test.13,16 In the present study, no markers for other
hypercoagulable states were analyzed. 
Eleven patients who had an APC ratio greater
than 2.6 had the factor V Leiden gene mutation and
only 67% of those with an APC ratio below 2.6 had
the mutation, illustrating the APC-resistance screen-
ing test’s weakness in being specific for the factor V
mutation. A variety of screening techniques have
been used. Recently, our laboratory has used factor
V depleted plasma for the APC-resistance screening
test. This has been found to be more accurate and
specific for confirmation of the factor V Leiden gene
mutation.16 It is not known which test should be
used in vascular surgery patients. Maybe the old, less
specific APC-ratio test has a higher predictive value
for graft occlusions than a more specific APC-resis-
tance test or the determination of the factor V
Leiden gene mutation.
In summary, a high frequency of the factor V
Leiden gene mutation and abnormal APC ratios was
found in patients with lower extremity peripheral
occlusive vascular disease. This finding was seen in
almost half of early vascular reconstructions that
thrombosed. The importance of APC resistance and
abnormal APC ratio needs to be studied further.
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